Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.5674 EUR
−10.94 M EUR
17.32 M EUR
2.43 M
About Ekso Bionics Holdings, Inc.
Sector
Industry
CEO
Scott G. Davis
Website
Headquarters
San Rafael
Founded
2012
ISIN
US2826444000
Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Ekso Bionics Holdings, Inc. stocks are traded under the ticker A4197U.
We've gathered analysts' opinions on Ekso Bionics Holdings, Inc. future price: according to them, A4197U price has a max estimate of 51.96 EUR and a min estimate of 8.23 EUR. Watch A4197U chart and read a more detailed Ekso Bionics Holdings, Inc. stock forecast: see what analysts think of Ekso Bionics Holdings, Inc. and suggest that you do with its stocks.
Yes, you can track Ekso Bionics Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
Ekso Bionics Holdings, Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
A4197U earnings for the last quarter are −1.05 EUR per share, whereas the estimation was −1.15 EUR resulting in a 8.15% surprise. The estimated earnings for the next quarter are −0.82 EUR per share. See more details about Ekso Bionics Holdings, Inc. earnings.
Ekso Bionics Holdings, Inc. revenue for the last quarter amounts to 1.75 M EUR, despite the estimated figure of 3.66 M EUR. In the next quarter, revenue is expected to reach 3.54 M EUR.
A4197U net income for the last quarter is −2.30 M EUR, while the quarter before that showed −2.67 M EUR of net income which accounts for 13.94% change. Track more Ekso Bionics Holdings, Inc. financial stats to get the full picture.
No, A4197U doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 15, 2025, the company has 61 employees. See our rating of the largest employees — is Ekso Bionics Holdings, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ekso Bionics Holdings, Inc. EBITDA is −9.10 M EUR, and current EBITDA margin is −49.38%. See more stats in Ekso Bionics Holdings, Inc. financial statements.
Like other stocks, A4197U shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ekso Bionics Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.